June 16, 2011 08:15 ET

SCYNEXIS and TB Alliance Sign HEOS Software Agreement

RESEARCH TRIANGLE PARK, NC--(Marketwire - Jun 16, 2011) - Drug discovery company SCYNEXIS, Inc. announced today that it has signed an agreement that provides TB Alliance with access to SCYNEXIS' proprietary HEOS® drug discovery software platform for use in the organization's global tuberculosis research activities.

HEOS is a SaaS, secure, cloud-based drug research information software platform that supports geographically-dispersed project scientists who may be in different organizations. It facilitates researchers' efforts to consolidate, manage, share and analyze -- with state-of-the-art tools -- complex drug discovery information on a global basis.

"SCYNEXIS is pleased that TB Alliance has chosen HEOS to support its worldwide network of researchers," said SCYNEXIS President and Chief Executive Officer Yves Ribeill. "In addition to being used for a number of years with SCYNEXIS' big pharma and biotech customers, HEOS has become the standard collaborative research software platform in the Global Health area."


SCYNEXIS delivers integrated, efficient and innovative drug discovery and development solutions to our global health and pharmaceutical partners. Our record of success is exemplified by the delivery of eleven pre-clinical drug candidates over the last five years. SCYNEXIS' teams are tailored to be especially effective in moving customer projects from concept to clinic, utilizing powerful proprietary technologies such as the HEOS® SaaS Software Platform for comprehensive drug discovery information management and the MEDCHEM-FACTORY® High-Throughput Synthesis and Purification Platform. Our fully-integrated contract research solutions include medicinal chemistry, advanced biological screening, in vitro pharmacology and ADMET-PK, bioanalytical and analytical chemistry, process chemistry and cGMP manufacturing.

Founded in 2000, SCYNEXIS is located in Research Triangle Park, North Carolina. To learn more, visit

About HEOS
HEOS® is a cloud-based software suite that provides a comprehensive array of web-based drug research information management software which supports geographically distributed scientists and facilitates collaboration.

The complex process of transforming a hit into a clinical candidate involves data generated by a broad range of sources. The success of the project relies on the capability of the partners to easily, securely and efficiently access, share and communicate the right information at the right time. HEOS is a web portal that provides a secure and user-friendly data handling system. It allows all the involved collaborators to view results and make informed decisions.

HEOS is powered by Accelrys tools including Accord data cartridge and Pipeline Pilot which are provided under special arrangement by Accelrys for use in neglected disease research.

Reference: Informatics for neglected diseases collaborations - F Bost, RT Jacobs, P Kowalczyk. Current Opinion in Drug Discovery & Development 2010 13:286-296.

Contact Information

  • For further information, please contact:
    SCYNEXIS, Inc.
    Terry Marquardt
    Executive Director
    Market Development & Communications
    Tel: +1-919-544-8603

    SCYNEXIS Media Contacts:
    Rick Rountree
    Rick Rountree Communications, Inc.
    Tel. +1 919-878-1144

    Sarah Cavanaugh
    MacDougall Biomedical Communications
    Tel. +1 781-235-3060